Cargando…

Postoperative survival According to the Glasgow Prognostic Score in Patients with Resected Lung Adenocarcinoma

BACKGROUND: The Glasgow Prognostic Score (GPS) is calculated from measured CRP and albumin levels. We here evaluated the significance of the GPS in patients with resected pulmonary adenocarcinoma. MATERIALS AND METHODS: The present study included 156 patients with lung adenocarcinoma who underwent l...

Descripción completa

Detalles Bibliográficos
Autores principales: Machida, Yuichiro, Sagawa, Motoyasu, Tanaka, Makoto, Motono, Nozomu, Matsui, Takuma, Usuda, Katsuo, Uramoto, Hidetaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454616/
https://www.ncbi.nlm.nih.gov/pubmed/27892939
http://dx.doi.org/10.22034/APJCP.2016.17.10.4677
_version_ 1783240860786229248
author Machida, Yuichiro
Sagawa, Motoyasu
Tanaka, Makoto
Motono, Nozomu
Matsui, Takuma
Usuda, Katsuo
Uramoto, Hidetaka
author_facet Machida, Yuichiro
Sagawa, Motoyasu
Tanaka, Makoto
Motono, Nozomu
Matsui, Takuma
Usuda, Katsuo
Uramoto, Hidetaka
author_sort Machida, Yuichiro
collection PubMed
description BACKGROUND: The Glasgow Prognostic Score (GPS) is calculated from measured CRP and albumin levels. We here evaluated the significance of the GPS in patients with resected pulmonary adenocarcinoma. MATERIALS AND METHODS: The present study included 156 patients with lung adenocarcinoma who underwent lobectomy at Kanazawa Medical University between 2002 and 2012. CLASSIFICATION WAS INTO THREE GROUPS: Those with normal albumin (>=3.5 g/dl) and C-reactive protein (CRP) (<=1.0 mg/dl) levels were classified as GPS 0 (n =136), those with low albumin (<3.5 g/dl) or elevated CRP (>1.0 mg/dl) levels as GPS 1 (n = 16), and those with low albumin (<3.5 g/dl) and elevated CRP (>1.0 mg/dl) levels as GPS 2 (n = 4). We retrospectively investigated relationships between the patient characteristics including the GPS, and disease-free survival and cancer-specific survival. RESULTS: The pathological stages of the patients were as follows: IA (n=78, 50%), IB (n=31, 19.9%), IIA (n=20.0, 12.8%), IIB (n=9.0, 5.7%), and IIIA (n=18.0, 11.5%). Lobectomy was performed in all cases. The average GPS was 0.15 (0-2) and showed significant relationships with stage and tumor size. The 2-year survival rates in patients with GPS0, 1 and 2 were 81.4%, 38.4%, and 25.0%, respectively. Clear correlations were noted with both cancer-specific survival and disease-free survival. Furthermore, multivariate analysis revealed that GPS was a significant prognostic factor. CONCLUSIONS: The GPS could be a prognostic factor for patients with resected pulmonary adenocarcinoma.
format Online
Article
Text
id pubmed-5454616
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-54546162017-08-28 Postoperative survival According to the Glasgow Prognostic Score in Patients with Resected Lung Adenocarcinoma Machida, Yuichiro Sagawa, Motoyasu Tanaka, Makoto Motono, Nozomu Matsui, Takuma Usuda, Katsuo Uramoto, Hidetaka Asian Pac J Cancer Prev Research Article BACKGROUND: The Glasgow Prognostic Score (GPS) is calculated from measured CRP and albumin levels. We here evaluated the significance of the GPS in patients with resected pulmonary adenocarcinoma. MATERIALS AND METHODS: The present study included 156 patients with lung adenocarcinoma who underwent lobectomy at Kanazawa Medical University between 2002 and 2012. CLASSIFICATION WAS INTO THREE GROUPS: Those with normal albumin (>=3.5 g/dl) and C-reactive protein (CRP) (<=1.0 mg/dl) levels were classified as GPS 0 (n =136), those with low albumin (<3.5 g/dl) or elevated CRP (>1.0 mg/dl) levels as GPS 1 (n = 16), and those with low albumin (<3.5 g/dl) and elevated CRP (>1.0 mg/dl) levels as GPS 2 (n = 4). We retrospectively investigated relationships between the patient characteristics including the GPS, and disease-free survival and cancer-specific survival. RESULTS: The pathological stages of the patients were as follows: IA (n=78, 50%), IB (n=31, 19.9%), IIA (n=20.0, 12.8%), IIB (n=9.0, 5.7%), and IIIA (n=18.0, 11.5%). Lobectomy was performed in all cases. The average GPS was 0.15 (0-2) and showed significant relationships with stage and tumor size. The 2-year survival rates in patients with GPS0, 1 and 2 were 81.4%, 38.4%, and 25.0%, respectively. Clear correlations were noted with both cancer-specific survival and disease-free survival. Furthermore, multivariate analysis revealed that GPS was a significant prognostic factor. CONCLUSIONS: The GPS could be a prognostic factor for patients with resected pulmonary adenocarcinoma. West Asia Organization for Cancer Prevention 2016 /pmc/articles/PMC5454616/ /pubmed/27892939 http://dx.doi.org/10.22034/APJCP.2016.17.10.4677 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
Machida, Yuichiro
Sagawa, Motoyasu
Tanaka, Makoto
Motono, Nozomu
Matsui, Takuma
Usuda, Katsuo
Uramoto, Hidetaka
Postoperative survival According to the Glasgow Prognostic Score in Patients with Resected Lung Adenocarcinoma
title Postoperative survival According to the Glasgow Prognostic Score in Patients with Resected Lung Adenocarcinoma
title_full Postoperative survival According to the Glasgow Prognostic Score in Patients with Resected Lung Adenocarcinoma
title_fullStr Postoperative survival According to the Glasgow Prognostic Score in Patients with Resected Lung Adenocarcinoma
title_full_unstemmed Postoperative survival According to the Glasgow Prognostic Score in Patients with Resected Lung Adenocarcinoma
title_short Postoperative survival According to the Glasgow Prognostic Score in Patients with Resected Lung Adenocarcinoma
title_sort postoperative survival according to the glasgow prognostic score in patients with resected lung adenocarcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454616/
https://www.ncbi.nlm.nih.gov/pubmed/27892939
http://dx.doi.org/10.22034/APJCP.2016.17.10.4677
work_keys_str_mv AT machidayuichiro postoperativesurvivalaccordingtotheglasgowprognosticscoreinpatientswithresectedlungadenocarcinoma
AT sagawamotoyasu postoperativesurvivalaccordingtotheglasgowprognosticscoreinpatientswithresectedlungadenocarcinoma
AT tanakamakoto postoperativesurvivalaccordingtotheglasgowprognosticscoreinpatientswithresectedlungadenocarcinoma
AT motononozomu postoperativesurvivalaccordingtotheglasgowprognosticscoreinpatientswithresectedlungadenocarcinoma
AT matsuitakuma postoperativesurvivalaccordingtotheglasgowprognosticscoreinpatientswithresectedlungadenocarcinoma
AT usudakatsuo postoperativesurvivalaccordingtotheglasgowprognosticscoreinpatientswithresectedlungadenocarcinoma
AT uramotohidetaka postoperativesurvivalaccordingtotheglasgowprognosticscoreinpatientswithresectedlungadenocarcinoma